LEQSELVI

Growth

deuruxolitinib phosphate

NDAORALTABLET
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100

Mechanism of Action

(JAK) inhibitor. JAKs mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent…

Loss of Exclusivity

LOE Date
Oct 10, 2044
226 months away
Patent Expiry
Oct 10, 2044
Exclusivity Expiry
Jul 25, 2029

Patent Records (5)

Patent #ExpiryTypeUse Code
10561659
May 4, 2037
U-3976
12076323
May 4, 2037
U-3976
11919907
May 21, 2041
Product
U-3976
12285432
Aug 11, 2042
U-3976
12247034
May 10, 2044
SubstanceProduct